Calimmune CEO Louis Breton Named to PharmaVOICE 100 for 2016

TUCSON, Ariz.–(BUSINESS WIRE)–Calimmune, Inc., a clinical-stage gene therapy company, is pleased to
announce that its Chief Executive Officer, Louis Breton, has been
selected by PharmaVOICE
magazine as one of the top 100 most inspirational and extraordinary
leaders in the life sciences industry for 2016.

“I am honored and humbled to have been selected by PharmaVOICE,” said
Mr. Breton. “It is a privilege to be among other leaders as we give
ourselves to a common goal: to alleviate human suffering by advancing
disease treatment options.”

Mr. Breton has become a prominent voice over the past decade for
improving access to gene therapies as a means to create a better quality
of life for individuals struggling with incurable and chronic diseases.

Calimmune is focused on developing gene therapies that enhance the
body’s own defenses to defeat disease. Under Mr. Breton’s leadership,
Calimmune’s lead program for treatment of HIV positive patients for whom
traditional treatments are not effective has advanced to Phase I/II
clinical trials. Advances in this program will establish Calimmune as a
leader in ex-vivo gene therapy (gene modification of the patient’s own
cells performed outside the body for reinfusion). Calimmune is building
on this platform with next-generation gene therapy programs directed
toward new outpatient treatments for hematologic diseases.

About Calimmune

Calimmune Inc. is a clinical-stage, international biotechnology company
focused on developing novel gene therapies that have the potential to
improve and protect the lives of patients by enhancing their immune
system. Calimmune’s lead therapeutic candidate, now in Phase I/II
clinical studies, is being evaluated as a one-time treatment to prevent
HIV progression to AIDS. Calimmune’s development pipeline includes
additional outpatient treatments for hematologic diseases. The company’s
clinical and laboratory operations are based in Pasadena, California and
Sydney, Australia. Calimmune’s corporate office is located in Tucson,
Arizona.

Contacts

Calimmune Inc.
Casey Sankey, 310-806-6240 x105
Director of
Communications
casey.sankey@calimmuneinc.com
or
Canale
Communications
Mark Corbae, 619-849-5375
Vice President
mark@canalecomm.com